Microbot Medical Continues to Strengthen Commercial Capabilities in Preparation for the anticipated Q3 2025 Launch of its LIBERTY® Endovascular Robotic System
HINGHAM, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY Endovascular Robotic System, today announced the continued expansion of its commercial team in preparation for the anticipated U.S. launch of the LIBERTY System, which is projected during the third quarter of 2025. The Company remains actively engaged with the U.S. Food and Drug Administration (FDA), with a 510(k) decision now expected during the third quarter of this year. This updated FDA decision timeline remains within the FDA's original scheduled review window and is not expected to affect the Company's planned launch upon clearance.
'Our recent interactions with the FDA have been productive, and we remain confident in the process and outcome,' said Harel Gadot, Chairman, CEO & President. 'We continue to operate with full momentum and position the Company for an anticipated launch during the third quarter of this year, which includes the continued build out of our commercial infrastructure and preparing the organization to deliver on our strategy.'
As part of the Company's ongoing launch preparation, it recently expanded its commercial team with the addition of Michael Lytle as the head of Sales Operations & Analytics. Mr. Lytle brings deep experience in sales support, data analysis, and operational excellence. He is expected to play a key role in shaping market intelligence tools and processes to optimize the sales cycle and drive strategic growth.
Prior to joining Microbot, Mr. Lytle held increasing leadership roles at ZOLL Cardiac Management Solutions (CMS), a division of ZOLL Medical Corporation, where he supported the rollout of innovative cardiac care technologies.
'We believe that Michael's addition will strengthen our launch readiness plans, and that his expertise will help us target the right markets, allocate resources effectively, and accelerate commercial execution,' concluded Mr. Gadot.
The LIBERTY System is currently under FDA review, is not available for sales in the US, and clearance is not guaranteed.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to redefine endovascular robotics and improve the quality of care for millions of patients and providers globally. The Company has developed the world's first single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems.
Further information about Microbot Medical® is available at http://www.microbotmedical.com.
Safe Harbor
Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as 'will,' 'believes,' 'plans,' 'anticipates,' 'expects' and 'estimates') should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, the Company's need for and ability to obtain additional working capital to continue its transition to a commercially focused company, market conditions, risks inherent in the development and/or commercialization of the LIBERTY® Endovascular Robotic System, uncertainty in the results of regulatory pathways and regulatory approvals, including whether the FDA will timely grant 510(k) clearance to commercially market the LIBERTY® Endovascular Robotic System in the United States if at all, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading 'Risk Factors' in Microbot Medical's periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC's web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
40 minutes ago
- Globe and Mail
Analysts: 1 Thing Apple Could Do to Make AAPL Stock a Buy Again Now
Apple (AAPL) remains one of the world's most valuable companies, but recent market performance and analyst sentiment suggest cracks in its premium valuation. Needham downgraded AAPL to 'Hold,' in part based on decelerating earnings growth, constrained innovation in generative AI, and mounting pressures on the commission-based model of the App Store. Analyst Laura Martin also emphasized that Apple could materially improve its bull case by 'aggressively pursuing' advertising revenue, an underdeveloped but potentially lucrative growth channel. With the stock still trading at over 26 times forward earnings, above the company's 10-year median and the S&P 500 Index ($SPX) in general, shareholders are questioning the growth thesis. Apple's Q2 FY2025 results displayed modest gains, with a 5% year-over-year increase in revenue to $95.4 billion and a rise in EPS of 8% to $1.65. Those gains, however, are behind those of competitors such as Amazon (AMZN) and Google (GOOGL), which exhibited much greater margin expansion and accelerating revenue. While Apple is still a powerhouse in premium hardware, analysts contend that its ecosystem requires a fresh growth trigger, such as advertising. About Apple Stock Apple (AAPL) is mega-cap tech giant focused on consumer electronics, software, and online services. Based in Cupertino, California, Apple has a market cap above $3 trillion fueled by flagship devices like the iPhone, iPad, and Mac, and cloud-based services like iCloud and Apple Music. AAPL shares have fallen about 21% from their 52-week high point of $260.10, most recently priced at about $205. After a brief recovery, the stock continues to trail the S&P 500's small YTD return of 2.1%. Some analysts now see lower levels, in the range of $170 to $180, as a reasonable point to enter, citing valuation issues and competition concerns. The company is priced at 28.2x forward earnings and 7.66x price-sales. While these are roughly in line with its five-year averages, they are rich valuations that are causing some investors to take a second look. Although Apple does pay a dividend, it is modest at $1.04 per share, and the company's recent share buyback authorization of $100 billion is still the focal point of its capital return policy. Apple Beats Q2 Earnings, But Forward Momentum Slows Apple reported fiscal Q2 results, besting Wall Street forecasts in terms of both revenue and EPS. It reported $95.4 billion in revenue, an increase of 5% year-over-year, and EPS of $1.65, an increase of 8%. Operating cash flow totaled $24 billion, powering a staggering $29 billion return to shareholders in the form of dividends and repurchases. In the future, however, Apple's growth trajectory looks to be less impressive. Already priced in is the iPhone 16e launch, so flat top-line growth is predicted by analysts for fiscal 2025. Further, Apple's heavy exposure to hardware sales makes it susceptible to macroeconomic slowdowns and competition. Regulatory danger also lurks in the wings. Apple's App Store 'platform tax,' a 15%–30% cut on in-app transaction income, is under international scrutiny. Regulators and competitors are trying to dismantle this stream of income, presently one of the major drivers of Services segment profits. What Analysts Project for Apple Stock Apple is graded a 'Moderate Buy' by Barchart's 37 analysts in coverage, but recent sentiment is weaker. The average 12-month target price of AAPL is at $231.02, signaling 13% upside from current prices. The highest estimate is at $300, signaling best-case upside of almost 50%, and the lowest of $141, signaling worst-case downside of roughly 30%. This broad range is a reflection of the unclear path of Apple's growth story.
Globe and Mail
40 minutes ago
- Globe and Mail
Top Analyst Ratings: June 9th, 2025
Top Ratings: (MSFT) (BA) (IBM) (JNJ) (TSLA) Adobe received a update from TD Cowen, with the analyst maintaining a Hold rating and setting a price target of $490 as of June 9, 2025. Boeing was maintained at Outperform by RBC, with the price target raised from $200 to $230 on June 9, 2025. Cisco was maintained at an Overweight rating by J.P. Morgan Chase & Co, with a price target of $73 on June 9, 2025. Costco was downgraded from Buy to Hold by Truist Financial, with a price target set at $1100 on June 9, 2025. IBM was maintained at a Buy rating by Bank of America Merrill Lynch, with the price target increased from $270 to $290 as of June 9, 2025. Johnson & Johnson received a target update from Bank of America Merrill Lynch, with the analyst maintaining a Neutral rating and raising the price target from $159 to $161 on June 9, 2025. McDonald's was reiterated at an Equal Weight rating by Morgan Stanley & Co., with a price target of $324 on June 9, 2025. Microsoft was maintained at a Hold rating by Morningstar, with a price target of $505 as of June 9, 2025. Oracle had its price target raised by BMO Capital Markets, with the analyst maintaining a Market Perform rating and increasing the target from $175 to $200 on June 9, 2025. Tesla received two separate updates: Robert W. Baird & Co. reiterates with a Neutral rating and price target of $320. Morgan Stanley & Co. maintained their Buy rating and setting a price target of $410, on June 9, 2025.
CTV News
43 minutes ago
- CTV News
Democrats are drawing closer to the crypto industry despite Trump divisions
An advertisement for the cryptocurrency, Bitcoin, is displayed on a building in Hong Kong on Nov. 18, 2021. (AP Photo/Kin Cheung, File) WASHINGTON — As U.S. President Donald Trump builds a crypto empire — including hosting a private dinner with top investors at his golf club — Democrats have united in condemning what they call blatant corruption from the White House. But the Democratic Party's own relationship with the emerging crypto industry is far less cut and dried. Work in the Republican-led Senate to legitimize cryptocurrency by adding guardrails has drawn backing from some Democrats, underscoring growing support for the industry in the party. But divisions have opened over the bill, with many demanding it prevent the Republican president and his family from directly profiting from cryptocurrency. 'I'm all on board with the idea of regulating crypto,' said Sen. Chris Murphy, D-Conn. 'But at this moment, when cryptocurrency is being so clearly used by Donald Trump to facilitate his corruption, I don't think you can close your eyes to that when you're legislating.' The legislation is moving ahead more rapidly than Congress usually acts when an industry is new. But the big money and campaign donations flowing from cryptocurrency firms have made them a new powerhouse on the political scene, one that's increasingly gaining allies and capturing the attention of lawmakers. A look at what to know about the industry's clout and the political fight over what's known as the GENIUS Act: 'Anti-crypto is a good way to end your career' To understand the growing clout of the crypto industry, look no further than the 2024 election. Fairshake, a crypto super political action committee, and its affiliated PACs spent more than US$130 million in congressional races. Fairshake spent roughly $40 million supporting Republican Bernie Moreno in Ohio in an effort to defeat Democratic Sen. Sherrod Brown. Brown, who lost to Moreno by more than 3 percentage points, was seen as a chief critic of the industry as the chairman of the Senate Banking Committee. 'DC received a clear message that being anti-crypto is a good way to end your career, as it doesn't represent the will of the voters,' Brian Armstrong, the CEO of Coinbase, wrote in a social media post the day after the 2024 election. Coinbase — the largest crypto exchange in the U.S. and biggest contributor to Fairshake — does not view support for its industry as partisan, according to Kara Calvert, the company's vice president of U.S. policy. The industry also spent heavily to support Democrats Ruben Gallego and Elissa Slotkin in their races for open Senate seats in battleground states. Fairshake spent $10 million in support of Slotkin during her successful Senate run against Republican Mike Rodgers, and Slotkin, who won the Michigan race by fewer than 20,000 votes, spoke in favor of crypto on the campaign trail. Similar dynamics are setting up ahead of 2026 in contested House and Senate races. Fairshake said in January that it already had $116 million in cash on hand aimed at the 2026 midterm elections. 'We're not slowing down, and everything remains on the table,' Josh Vlasto, a spokesperson for Fairshake, told The Associated Press. Hours before a May 19 vote to move forward on cryptocurrency legislation in the Senate, an advocacy group tied to Coinbase sent an email to the offices of U.S. senators warning that the vote would count toward their crypto-friendliness scores. 'What the spending does is put crypto on the map. It lets members know that this is not a phase, this is real industry, with real dollars, that is developing its hold in Washington,' said Calvert. Democrats navigate around a 'crypto president' A significant number of Democrats, 16, joined Republicans in advancing the crypto legislation. The GENIUS Act would create a new regulatory structure for stablecoins, a type of cryptocurrency typically pegged to the U.S. dollar. It is viewed as a step toward consumer protections and greater legitimacy for the industry. The sticking point for many Democrats is that while the bill prohibits members of Congress and their families from profiting off stablecoins, it excludes the president from those restrictions. Trump, once a skeptic of the industry, has vowed in his second term to make the U.S. the global capital of crypto. Meanwhile, he and his family have moved aggressively into nearly every corner of the industry: mining operations, billion-dollar bitcoin purchases, a newly minted stablecoin and a Trump-branded meme coin. Days after Trump's interests in the industry became public in early May, Senate Minority Leader Chuck Schumer of New York urged the Democratic caucus to unite and vote against the package to have a stronger hand in negotiations, according to a person familiar with the matter who insisted on anonymity to discuss private discussions. On May 8, a bloc of Senate Democrats who had previously backed the GENIUS Act reversed course — ultimately voting to block the bill from advancing. Negotiations between Senate Democrats and Republicans followed. The new version of the bill is now expected to pass the 100-member Senate this month. Amendments are still possible. Schumer and Sen. Jeff Merkley, D-Ore. are expected to propose one that would bar the president and his family from profiting off stablecoins, though it's unlikely to pass. 'There is room for improvements as there often is with a lot of legislation. But with this in particular, we've got issues with the president,' said Democratic Sen. Mark Kelly of Arizona 'Having said that, this was negotiated with Democrats and Republicans. We got to a place. We voted on it. I expect this is the version we're going to pass.' Still, the legislation is stirring unease. Schumer, asked if he's urging members to vote against the bill, noted that he has opposed the legislation and said 'there's division in our caucus on that issue.' 'There's a gaping hole in this bill that everybody sees,' Murphy said. 'After it's passed, it will be illegal for me to issue a cryptocurrency, but it's legal for the president of the United States.' 'If this bill passes, we kind of go from a dirt road to a paved road,' he said. What comes next If the Senate approves the stablecoin legislation, the bill will still need to clear the House before reaching the president's desk. Crypto advocates say the next priority is pushing Congress for market structure legislation, a far more sweeping effort than simply regulating stablecoins. 'Stablecoin is one step of the path. Then you need market structure. We're hopeful that the Senate works together to pass something quickly,' Calvert said. Some Democrats view the legislation as a chance to impose basic guardrails on a rapidly growing industry that's particularly popular among men and younger voters, two groups that drifted from the party in 2024. ___ Associated Press writers Alan Suderman, Lisa Mascaro, Matt Brown and Mary Clare Jalonick contributed to this report. Joey Cappelletti, The Associated Press
